Sarepta released three‑year follow‑up data showing durable motor function benefits for patients treated with Elevidys (delandistrogene moxeparvovec) relative to external controls. The company says the gap in key outcomes widened between years two and three, positioning the therapy’s long‑term efficacy as a counterpoint to prior safety and commercialization headwinds. Investors reacted positively and Sarepta framed the data as central to rebuilding confidence in Elevidys uptake and payer discussions. The company still faces questions about labeling, sales momentum and long‑term safety monitoring as it tries to translate durable outcomes into market growth.